Accéder au contenu
Merck

Congenital sucrase-isomaltase deficiency: identification of a common Inuit founder mutation.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2014-12-03)
Julien L Marcadier, Margaret Boland, C Ronald Scott, Kheirie Issa, Zaining Wu, Adam D McIntyre, Robert A Hegele, Michael T Geraghty, Matthew A Lines
RÉSUMÉ

Congenital sucrase-isomaltase deficiency is a rare hereditary cause of chronic diarrhea in children. People with this condition lack the intestinal brush-border enzyme required for digestion of di- and oligosaccharides, including sucrose and isomaltose, leading to malabsorption. Although the condition is known to be highly prevalent (about 5%-10%) in several Inuit populations, the genetic basis for this has not been described. We sought to identify a common mutation for congenital sucrase-isomaltase deficiency in the Inuit population. We sequenced the sucrase-isomaltase gene, SI, in a single Inuit proband with congenital sucrase-isomaltase deficiency who had severe fermentative diarrhea and failure to thrive. We then genotyped a further 128 anonymized Inuit controls from a variety of locales in the Canadian Arctic to assess for a possible founder effect. In the proband, we identified a novel, homozygous frameshift mutation, c.273_274delAG (p.Gly92Leufs*8), predicted to result in complete absence of a functional protein product. This change was very common among the Inuit controls, with an observed allele frequency of 17.2% (95% confidence interval [CI] 12.6%-21.8%). The predicted Hardy-Weinberg prevalence of congenital sucrase-isomaltase deficiency in Inuit people, based on this single founder allele, is 3.0% (95% CI 1.4%-4.5%), which is comparable with previous estimates. We found a common mutation, SI c.273_274delAG, to be responsible for the high prevalence of congenital sucrase-isomaltase deficiency among Inuit people. Targeted mutation testing for this allele should afford a simple and minimally invasive means of diagnosing this condition in Inuit patients with chronic diarrhea.

MATÉRIAUX
Numéro du produit
Marque
Description du produit

Sigma-Aldrich
Base Trizma®, Primary Standard and Buffer, ≥99.9% (titration), crystalline
Sigma-Aldrich
Base Trizma®, BioPerformance Certified, meets EP, USP testing specifications, suitable for cell culture, ≥99.9% (titration)
Sigma-Aldrich
Chlorure de potassium, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Tromethamine, meets USP testing specifications
Sigma-Aldrich
Sigma 7-9®, ≥99% (titration), powder or crystals
Sigma-Aldrich
Chlorure de potassium, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Supelco
Potassium chloride solution, ~3 M KCl, saturated with silver chloride
Sigma-Aldrich
Base Trizma®, ≥99.0% (T)
Sigma-Aldrich
Base Trizma®, anhydrous, free-flowing, Redi-Dri, ≥99.9%
Supelco
Chlorure de potassium solution, BioUltra, ~3 M in H2O
Sigma-Aldrich
Chlorure de potassium, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, ≥99%
Sigma-Aldrich
Base Trizma®, 99.7% (T), puriss. p.a.
Supelco
Base Trizma®, reference material for titrimetry, certified by BAM, >99.5%
USP
Tromethamine, United States Pharmacopeia (USP) Reference Standard
Trometamol, European Pharmacopoeia (EP) Reference Standard
Supelco
Chlorure de potassium solution, 1 M KCl
Supelco
Chlorure de potassium solution, conductance standard A acc. to ISO 7888, 0.1 M KCl
SAFC
Tromethamine
Supelco
Chlorure de potassium solution, conductance standard B acc. to ISO 7888, 0.01 M KCl
Supelco
Chlorure de potassium solution, conductance standard C acc. to ISO 7888, 0.001 M KCl
Sigma-Aldrich
Chlorure de potassium, tested according to Ph. Eur.